Department of Pediatrics, Division of Neonatal Medicine, University of Louisville School of Medicine, Louisville, KY, USA.
Department of Pediatrics, The Robert Larner, MD, College of Medicine, University of Vermont, Burlington, VT, USA.
J Perinatol. 2022 Mar;42(3):300-306. doi: 10.1038/s41372-021-01206-3. Epub 2021 Sep 23.
Neonates born to mothers taking opioids during pregnancy are at risk for neonatal opioid withdrawal syndrome (NOWS), for which there is no recognized standard approach to care. Nonpharmacologic treatment is typically used as a first-line approach for management, and pharmacologic treatment is added when clinical signs are not responding to nonpharmacologic measures alone. Although morphine and methadone are the most commonly used pharmacotherapies for NOWS, buprenorphine has emerged as a treatment option based on its pharmacologic profile and results from initial single site clinical trials. The objective of this report is to provide an overview of NOWS including a summary of ongoing work in the field and to review the state of the science, knowledge gaps, and practical considerations specific to the use of buprenorphine for the treatment of NOWS as discussed by a panel of experts during a virtual workshop hosted by the National Institutes of Health.
母亲在怀孕期间使用阿片类药物的新生儿有患新生儿阿片类戒断综合征（NOWS）的风险，目前对此尚无公认的标准护理方法。非药物治疗通常作为一线管理方法，当临床症状不能仅通过非药物措施得到缓解时，会添加药物治疗。虽然吗啡和美沙酮是最常用于治疗 NOWS 的药物治疗方法，但根据其药理学特征和最初的单站点临床试验结果，丁丙诺啡已成为一种治疗选择。本报告的目的是概述 NOWS，包括对该领域正在进行的工作的总结，并审查科学现状、知识空白以及在由美国国立卫生研究院主办的虚拟研讨会上，专家组讨论的丁丙诺啡治疗 NOWS 的具体实际考虑因素。
